KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Working Capital Changes (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Working Capital Changes for 16 consecutive years, with -$28.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 405.68% to -$28.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.0 million, a 715.35% increase, with the full-year FY2025 number at $33.0 million, up 715.35% from a year prior.
  • Other Working Capital Changes was -$28.4 million for Q4 2025 at Halozyme Therapeutics, down from $20.3 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $43.5 million in Q2 2024 to a low of -$38.5 million in Q3 2024.
  • A 5-year average of $1.6 million and a median of -$759000.0 in 2021 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: surged 58475.0% in 2021, then tumbled 529600.0% in 2022.
  • Halozyme Therapeutics' Other Working Capital Changes stood at $1000.0 in 2021, then crashed by 529600.0% to -$5.3 million in 2022, then surged by 71.31% to -$1.5 million in 2023, then tumbled by 270.05% to -$5.6 million in 2024, then plummeted by 405.68% to -$28.4 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Other Working Capital Changes are -$28.4 million (Q4 2025), $20.3 million (Q3 2025), and $36.1 million (Q2 2025).